Abbott outbids Biogen for Facet's multiple sclerosis antibody.
Sheridan
Cormac
C
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000191:economics / Q000458:organization & administration; D002986:Clinical Trials as Topic; D003164:Competitive Bidding; D000077561:Daclizumab; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration; D006801:Humans; D007074:Immunoglobulin G; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D000077561:Daclizumab
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
16585503
J Clin Immunol. 2007 Jan;27(1):1-18
17216565
Lancet Neurol. 2010 Apr;9(4):381-90
20163990